Genpharmasec Approves Subsidiary Divestment and CS Resignation
Genpharmasec Ltd · Change in Management · 03 Nov 2026, 11:08 pm
Genpharmasec Approves Subsidiary Divestment and CS Resignation Genpharmasec’s board approved the full divestment of its wholly owned subsidiary, Clinigenome India Private Limited, to Micro Genomics India Private Limited. Clinigenome contributed ₹100.47 Lakhs (0.72%) to consolidated turnover and had a net worth of ₹(154.41) Lakhs in the last financial year. The non-related-party transaction is slated for completion on or before 31st Mar'27, with financial consideration to be determined. Additionally, Company Secretary and Compliance Officer Hardik Makwana resigned, effective 16th Nov'26, to pursue external opportunities. Unaudited results for the period ended 30th Sep'26 were approved.
Original exchange filing (PDF)
More announcements from Genpharmasec Ltd
- Statement of deviation or variation in the use of proceeds of Rights Issue for the Quarter ended 30th September, 2026. · 03 Nov 2026
- Unaudited Standalone & consolidated Financial Result of the company for the quarter & half year ended 30th September 2026. · 03 Nov 2026
- Outcome of the Meeting of Board of Directors held on Tuesday, 03rd November, 2026. · 03 Nov 2026
- Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve 1. To consider and approve Un-audited .... · 03 Nov 2026
- Intimation under regulation 30 - Change of name of Subsidiary of the company. · 14 Oct 2026
- Disclosure of Voting Results and Scrutinizers report of the 34th Annual General Meeting held on 29th September, 2026. · 30 Sept 2026
- Submission of Proceeding of the 34th Annual General Meeting of the Member of the Genpharmasec Ltd held on Tuesday, 29th September, 2026. · 29 Sept 2026
- Annual Report for Financial Year 2025-26. · 07 Sept 2026
